Welcome to our dedicated page for Venus Concept news (Ticker: VERO), a resource for investors and traders seeking the latest updates and insights on Venus Concept stock.
Venus Concept Inc. (VERO) delivers innovative medical aesthetic and hair restoration technologies through its unique subscription-based model. This dedicated news hub provides investors and industry professionals with essential updates on corporate developments, product advancements, and strategic initiatives shaping the global aesthetics market.
Access real-time announcements including quarterly earnings reports, regulatory filings, technology launches, and partnership agreements. Our curated collection ensures you stay informed about VERO's minimally invasive treatment systems, international expansion efforts, and clinical research breakthroughs without promotional bias.
Key coverage areas include financial performance updates, new device approvals, practice support program enhancements, and market expansion activities. Each update is verified for accuracy and presented in clear, accessible language suitable for both professional investors and industry observers.
Bookmark this page for streamlined access to Venus Concept's evolving business narrative. Check regularly for authoritative reporting on how VERO continues integrating advanced technologies like radiofrequency systems and IPL platforms with practice growth initiatives across 60+ countries.
Venus Concept Inc. (NASDAQ: VERO) has announced the establishment of a medical advisory board for AI.ME, its next generation robotic platform for fractional skin resurfacing. The board, comprising six leading physicians, will provide strategic input and clinical recommendations for the technology, which received FDA 510(k) clearance in December 2022.
The advisory board includes renowned dermatologists and plastic surgeons: Dr. Glynis Ablon, Dr. Macrene Alexiades, Dr. Eric Bernstein, Dr. James Chao, Dr. Mitchel Goldman, and Dr. Gilly Munavalli. These experts will play a important role in defining AI.ME's commercialization strategy.
AI.ME is the first and only robotic system cleared by FDA for fractional skin resurfacing. It uses machine vision and AI algorithms to target the skin precisely and predictably. Venus Concept expects to begin clinical engagement with the advisory board members in the coming months, with a commercial launch anticipated in the second half of fiscal year 2024.
FAQ
What is the current stock price of Venus Concept (VERO)?
What is the market cap of Venus Concept (VERO)?
